Production (Stage)
Integrated Biopharma, Inc.
INBP
$0.29
-$0.0135-4.45%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 52.92M | 52.12M | 51.02M | 50.32M | 50.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.92M | 52.12M | 51.02M | 50.32M | 50.57M |
| Cost of Revenue | 47.55M | 47.05M | 46.60M | 46.43M | 46.98M |
| Gross Profit | 5.38M | 5.07M | 4.42M | 3.88M | 3.59M |
| SG&A Expenses | 3.54M | 3.63M | 3.63M | 3.63M | 3.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.09M | 50.68M | 50.22M | 50.07M | 50.64M |
| Operating Income | 1.83M | 1.45M | 795.00K | 251.00K | -72.00K |
| Income Before Tax | 1.88M | 1.46M | 818.00K | 268.00K | -63.00K |
| Income Tax Expenses | 627.00K | 527.00K | 388.00K | 156.00K | 53.00K |
| Earnings from Continuing Operations | 1.25 | 0.93 | 0.43 | 0.11 | -0.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.25M | 928.00K | 430.00K | 112.00K | -116.00K |
| EBIT | 1.83M | 1.45M | 795.00K | 251.00K | -72.00K |
| EBITDA | 2.17M | 1.78M | 1.13M | 570.00K | 244.00K |
| EPS Basic | 0.04 | 0.03 | 0.01 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.04 | 0.03 | 0.02 | 0.01 | 0.00 |
| EPS Diluted | 0.04 | 0.03 | 0.01 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.04 | 0.03 | 0.02 | 0.01 | 0.00 |
| Average Basic Shares Outstanding | 120.67M | 120.47M | 120.40M | 120.26M | 120.11M |
| Average Diluted Shares Outstanding | 124.17M | 123.40M | 122.20M | 121.51M | 122.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |